Article

1 Iconography
Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text
Advertising


Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates



Journal of the American Academy of Dermatology
Volume 80, n° 6
pages 1780-1782 (juin 2019)
Doi : 10.1016/j.jaad.2018.12.020
Research Letters

Tumor mutational burden and response to programmed cell death protein 1 inhibitors in a case series of patients with metastatic desmoplastic melanoma
 

Lise Boussemart, MD, PhD a, b, Adrienne Johnson, MSc c, Alexa B. Schrock, PhD, MD c, Sumanta K. Pal, MD d, Garrett M. Frampton, PhD c, David Fabrizio, BS c, Zachary Chalmers c, Michal Lotem, MD e, Geoffrey Gibney, MD f, Jeffery Russell, MD g, Bartosz Chmielowski, MD, PhD h, Jeffrey S. Ross, MD c, i, Phil J. Stephens, PhD c, Vincent A. Miller, MD c, Siraj M. Ali, MD, PhD c,
a Department of Dermatology, Pontchaillou Hospital, Centre Hospitalier Universitaire de Rennes, F-35000 Rennes, France 
b Université Rennes, Centre National de la Recherche Scientifique, Institut de Génétique and Développement de Rennes, UMR 6290, F-35000 Rennes, France 
c Foundation Medicine Inc, Cambridge, Massachusetts 
d Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, California 
e Department of Oncology, Hadassah Medical Center, Jerusalem, Israel 
f Georgetown-Lombardi Comprehensive Cancer Center, Washington DC 
g Moffitt Cancer Center, Tampa, Florida 
h Department of Medicine, Jonsson Comprehensive Cancer Center at the University of California Los Angeles, Los Angeles, California 
i Department of Pathology and Laboratory Medicine, Albany Medical College, Albany, New York 

Correspondence to: Siraj M. Ali, MD, PhD, Foundation Medicine Inc, 150 Second St, Second Floor, Cambridge, MA 02141Foundation Medicine Inc150 Second StSecond FloorCambridgeMA02141

 Dr Ross is currently affiliated with Upstate Medical University's Department of Pathology and Laboratory Medicine. Dr Russell is currently affiliated with Janssen Pharmaceuticals.
 Dr Boussemart, Ms Johnson, and Dr Schrock contributed to this work equally.
 Funding sources: None.
 Conflicts of interest: Ms Johnson, Dr Schrock, Dr Frampton, Mr Fabrizio, Mr Chalmers, Dr Ross, Dr Stephens, Dr Miller, and Dr Ali were employed by and held equity interest in Foundation Medicine Inc at the time this study was performed. Foundation Medicine Inc is now a wholly owned subsidiary of Roche. Dr Lotem is an employee of TEVA Pharmaceuticals. Dr Boussemart, Dr Pal, Dr Gibney, Dr Chmielowski, and Dr Russell have no conflicts of interest to disclose.
 Reprints not available from the authors.


Top of the page

© 2018  American Academy of Dermatology, Inc.@@#104156@@
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Close
Article Outline
You can move this window by clicking on the headline
@@#110903@@